SHANGHAI – Innovent Biologics Inc., of Suzhou, has kicked off two pivotal phase III trials in China for biosimilar antibodies of global blockbusters. Innovent's IBI301 will be tested in a head-to-head trial with Rituxan/Mabthera (rituximab, Roche AG) in patients with non-Hodgkin lymphoma and IBI303 will go up against Humira (adalimumab, Amgen Inc.) for the treatment of ankylosing spondylitis.
SHANGHAI – Asia's contender in the CRISPR patent battle is now a step closer to seeing global IP claims validated. Toolgen Inc., of Seoul, South Korea had two patent applications granted by the Korea Intellectual Property Office covering genome editing using the CRISPR platform.
SHANGHAI – Innovent Biologics Inc., of Suzhou, has kicked off two pivotal phase III trials in China for biosimilar antibodies of global blockbusters. Innovent's IBI301 will be tested in a head-to-head trial with Rituxan/Mabthera (rituximab, Roche AG) in patients with non-Hodgkin's lymphoma and IBI303 will go up against Humira (adalimumab, Amgen Inc.) for the treatment of ankylosing spondylitis.
SHANGHAI – China's regulatory authorities have given Beigene Co. Ltd., the green light to study BGB-A317, a fully human PD-1 antibody, on patients in China. But this is not the first time BGB-A317 will be tested in a phase I trial.
SHANGHAI – China's regulatory authorities have given Beigene Co. Ltd., the green light to study BGB-A317, a fully human PD-1 antibody, on patients in China. But this is not the first time BGB-A317 will be tested in a phase I trial.
Beijing Shenogen Pharma Group Ltd. has signed a co-development deal with Lee’s Pharmaceutical Holdings Ltd., of Hong Kong, to combine Shenogen’s lead compound, icaritin, a traditional Chinese medicine-derived small-molecule drug, with Pexa-Vec (JX-594, pexastimogene devacirepvec), an oncolytic virus being developed in China by Lee’s. The companies have high hopes that the combination will have a significant impact on Chinese patients with late-stage cancers, particularly advanced hepatocellular carcinoma (HCC).
SHANGHAI – Newly created oncology biotech, CBT Pharmaceuticals, of Santa Clara, Calif., has received $9.75 million in series A financing from venture investors led by Orbimed Healthcare Fund Management Asia, with an additional $2 million available in warrants. CBT Pharmaceuticals is an off-shoot of the discovery and preclinical service company, Crown Biosciences Inc. (Crownbio), which has research centers in China, U.K. and the U.S.
SHANGHAI – Newly created oncology biotech, CBT Pharmaceuticals, of Santa Clara, Calif., has received $9.75 million in series A financing from venture investors led by Orbimed Healthcare Fund Management Asia, with an additional $2 million available in warrants.
Beijing Shenogen Pharma Group Ltd. has signed a co-development deal with Lee's Pharmaceutical Holdings Ltd., of Hong Kong, to combine Shenogen's lead compound, icaritin, a traditional Chinese medicine-derived small-molecule drug, with Pexa-Vec (JX-594, pexastimogene devacirepvec), an oncolytic virus being developed in China by Lee's.
SHANGHAI – KBP Biosciences (China) Inc. is the brainchild of Zhenhua Huang, a Chinese serial entrepreneur that first found success with his earlier effort, Xuanzhu Pharma. Huang is a rare breed of biotech founder, China-born and educated, he has an international vision for KBP building on the lessons learned from more than a decade of doing business in China.
